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Abstract
A case of cavitary pulmonary disease caused by Mycobacterium heckeshornense in Uruguay is described. This is the ﬁrst case reported in the
Latin America and Caribbean region, showing that this species is a worldwide opportunistic human pathogen.
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In July 2013 a 53-year-old white homeless man with a history of
alcoholism was admitted to the hospital with long-standing
cough, fever and fatigue. Physical examination revealed malnu-
trition with severe weight loss, dyspnea and decreased lung
sounds primarily in the upper lobes. Chest radiograph and
computed tomographic imaging (Fig. 1) revealed bilateral upper
lobe inﬁltrates with cavitation. Haematological analysis revealed
a hemoglobin level of 9.8 g/dL and a leukocyte count of
6.9 × 109/L. HIV serology was negative. With a presumptive
diagnosis of tuberculosis, two serial sputum samples and a
bronchoalveolar lavage sample were sent to the national
tuberculosis reference laboratory. All direct smears (stained
with Auramine O and Ziehl-Neelsen) were positive for acid-fast
bacilli. Antituberculosis treatment was started, with isoniazid,
rifampicin, pyrazinamide and ethambutol (HRZE) provided
according to the guidelines of the National Program of
Tuberculosis of Uruguay. The bronchoalveolar lavage sample
was decontaminated with the N-acetyl-L-cysteine–sodium
hydroxide (NALC-NaOH) method and inoculated into myco-
bacterium growth indicator tubes (MGIT; BD Biosciences,
Sparks, MD, USA) automated liquid culture system. After 26
days of incubation, the MGIT culture ﬂagged positive; Ziehl-
Neelsen stain of liquid culture was positive for acid-fast
bacilli, and immunochromatographic test for the identiﬁcation
of Mycobacterium tuberculosis complex (TBC ID; Becton Dick-
inson, Franklin Lakes, NJ, USA) was negative. Cells were pel-
leted and DNA extracted. The GenoType Mycobacterium CM
(common mycobacteria) and AS (additional species) assays
(Hain Lifesciences, Nehren, Germany) for identiﬁcation of
nontuberculous mycobacteria were performed. The results
were positive for M. heckeshornense.
Subcultures on Ogawa medium, as well as the solid cultures
from the two sputum samples, yielded small, hemispheric,
smooth and yellow-pigmented colonies after 4 weeks of
incubation.
Phenotypic characterization was performed for all isolates
(Table 1), and DNA was submitted to the Institut Pasteur at
Montevideo for sequencing studies. To identify the isolates to
the species level, the complete 16S rDNA gene and a frag-
ment of hsp65 and rpoB genes were sequenced (GenBank
accession numbers KP636957, KP636958 and KP636959,
respectively). The DNA sequences obtained were compared
with the GenBank/European Molecular Biology Laboratory
sequence database. Gene sequencing unambiguously
conﬁrmed the identiﬁcation of M. heckeshornense (100%
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similarity with M. heckeshornense type strain sequences for all
targets). With these clinical, radiologic and microbiologic
ﬁndings, the patient met the American Thoracic Society/In-
fectious Diseases Society of America diagnostic criteria of
nontuberculous mycobacterial lung disease [1]. Treatment
was thus changed to isoniazid, rifampicin, ethambutol, levo-
ﬂoxacin and clarithromycin, all provided daily. Ethambutol had
to be stopped owing to ocular toxicity. The patient improved
clinically, and a regression of the lesions was observed
radiologically. After 12 months of treatment with the
macrolide-containing regimen, the patient had converted to
negative cultures, and treatment was stopped. After 12
months of follow-up, his disease is clinically and radiologically
stable and culture negative.
M. heckeshornense was ﬁrst reported in 2000 as a pathogenic,
slowly growing scotochromogenic mycobacterium, phyloge-
netically related to Mycobacterium xenopi, that caused a bilateral
cavitary lung disease in an immunocompetent patient [2]. Since
then, a limited number of cases were reported in humans, some
of them involving severe pulmonary infections [3–5] often
FIG. 1. Chest computed tomographic scan showing pulmonary inﬁltrates and cavities.
TABLE 1. Phenotypic characteristics of isolates from Uruguay and isolates originally reported asMycobacterium heckeshornense sp.
Feature Mycobacterium xenopi
Isolates from
Uruguay (n[ 3)
Isolates of M. heckeshornense sp. nov.a
S369 S532 S504
Morphology Smooth Smooth Smooth Smooth Smooth
Pigment Scotochromogen Scotochromogen Scotochromogen Scotochromogen Scotochromogen
Growth rate Slow Slow Slow Slow Slow
Growth at 37°C + + + + +
Growth at 42°C + + + + +
Niacin production − − − − −
Nitrate reduction − − − − −
Catalase (heat stable) −/+ + + + +
Arylsulfatase 3 days/14 days + (weak)/+ + (weak)/+ −/− −/− −/−
Pyrazinamide + + − − −
Tween 80 hydrolysis − − − − −
aIdentiﬁcation number of isolates obtained by Roth et al. [5].
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identiﬁed as M. xenopi and also involving extrapulmonary in-
fections [6–12]. Furthermore, it was isolated from animal
sources such as porcine lymph nodes [13] and from a domestic
cat with a severe generalized infection [14]. This could indicate
that this species is widely distributed in the environment. The
new commercially available molecular biology methods can fast
and precisely identify most common Mycobacterium species. In
our case, we identiﬁed correctly M. heckeshornense using the
Genotype CM/AS HAIN tests in 2 days.
The patient was treated with standard therapy (HRZE) for 2
months, until the diagnosis of M. heckeshornense was conﬁrmed.
In the absence of guidelines for the treatment of
M. heckeshornense disease, the patient was treated with isoniazid,
rifampicin, ethambutol, levoﬂoxacin and clarithromycin. This led
to prolonged culture conversion and no relapse 12 months after
treatment cessation. In some patients [5,7], resolution was
reached with surgical procedures. In our case, the extent of the
pulmonary lesions and the general condition of the patient pre-
vented this approach. Although M. heckeshornense is genetically
related to M. xenopi, its pathogenicity is noticeably higher [4].
Cases have been reported in Asia, Europe and recently in Canada
[7], showing thatM. heckeshornense is an opportunistic pathogen
present worldwide. This is the ﬁrst case reported in Uruguay and
the Latin America and Caribbean regions. A possible explanation
of this fact is that in many countries of this region, tuberculosis
disease is conﬁrmed only by microscopy; culture and identiﬁca-
tion, particularly molecular identiﬁcation, are not routinely done.
In summary, we describe a case of ﬁbrocavitary
M. heckeshornense pulmonary disease, the ﬁrst of its kind
described in the Latin America and Caribbean region. A
treatment regimen of isoniazid, rifampicin, clarithromycin and
levoﬂoxacin led to symptomatic improvement.
M. heckeshornense is a serious nontuberculous mycobacterial
pathogen with a worldwide spread.
Acknowledgements
Partially funded by FOCEM (MERCOSUR Structural Conver-
gence Fund), grant COF 03/11. GG, CR and CC are
researchers from the Sistema Nacional de Investigadores
(ANII), Uruguay.
Conﬂict of Interest
None declared.
References
[1] Grifﬁth DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C,
Gordin F, et al. An ofﬁcial ATS/IDSA statement: diagnosis, treatment,
and prevention of nontuberculous mycobacterial diseases. Am J Respir
Crit Care Med 2007;175:367–416.
[2] Morimoto K, Kazumi Y, Maeda S, Yoshimori K, Yoshiyama T, Ogata H,
et al. Mycobacterium heckeshornense lung infection that was diagnosed
as Mycobacterium xenopi disease by DNA-DNA hybridization (DDH).
Intern Med 2011;50(11):1251–3. Epub 2011 Jun 1.
[3] Hisamoto A, Ozaki S, Sakugawa M, Komoto R, Tamaoki A, Miyake T,
et al. [A possible case of pulmonary infection due to Mycobacterium
heckeshornense]. Nihon Kokyuki Gakkai Zasshi 2008;46:1019–23.
[4] Jaureguy F, Ioos V, Marzouk P, Hornstein M, Picard B, Gutierrez MC,
et al. Mycobacterium heckeshornense: an emerging pathogen responsible
for a recurrent lung infection. J Infect 2007;54:e33–5.
[5] Roth A, Reischl U, Schonfeld N, Naumann L, Emler S, Fischer M, et al.
Mycobacterium heckeshornense sp. nov., a new pathogenic slowly
growing Mycobacterium sp. causing cavitary lung disease in an immu-
nocompetent patient. J Clin Microbiol 2000;38:4102–7.
[6] Ahmed RA, Miedzinski LJ, Shandro C. Mycobacterium heckeshornense
infection in HIV-infected patient. Emerg Infect Dis 2010;16:1801–3.
[7] Chan WW, Murray MC, Tang P, Romney MG. Mycobacterium heck-
eshornense peritonitis in a peritoneal dialysis patient: a case report and
review of the literature. Clin Microbiol Infect 2011;17:1262–4.
[8] Elyousﬁ AA, Leiter JR, Goytan MJ, Robinson DB. Mycobacterium
heckeshornense lumbar spondylodiskitis in a patient with rheumatoid
arthritis receiving etanercept treatment. J Rheumatol 2009;36:2130–1.
[9] Godreuil S, Marchandin H, Terru D, Le Moing V, Chammas M,
Vincent V, et al. Mycobacterium heckeshornense tenosynovitis. Scand J
Infect Dis 2006;38:1098–101.
[10] McBride SJ, Taylor SL, Pandey SK, Holland DJ. First case of Mycobac-
terium heckeshornense lymphadenitis. J Clin Microbiol 2009;47:268–70.
[11] Kazumi Y, Sugawara I, Wada M, Kimura K, Itono H. [Microbiologically
identiﬁed isolates of Mycobacterium heckeshornense in two patients].
Kekkaku 2006;81:603–7.
[12] van Hest R, van der Zanden A, Boeree M, Kremer K, Dessens M,
Westenend P, et al. Mycobacterium heckeshornense infection in an
immunocompetent patient and identiﬁcation by 16S rRNA sequence
analysis of culture material and a histopathology tissue specimen. J Clin
Microbiol 2004;42:4386–9.
[13] van Ingen J, Wisselink HJ, van Solt-Smits CB, Boeree MJ, van
Soolingen D. Isolation of mycobacteria other than Mycobacterium avium
from porcine lymph nodes. Vet Microbiol 2010;144:250–3.
[14] Elze J, Grammel L, Richter E, Aupperle H. First description of Myco-
bacterium heckeshornense infection in a feline immunodeﬁciency
virus–positive cat. J Feline Med Surg 2013;15:1141–4.
NMNI Coitinho et al. M. heckeshornense cavitary lung disease 65
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 9, 63–65
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
